Sign in:
 Email
 Password  save:
  
 Company Reports 
 
 
Membership is free, please Sign Up.
  
My Recent Searches
  Help
  
   
 
 
Get Insiders for : 
Keros Therapeutics, Inc. (KROS)  
$0.00 0.00 (0.00%) as of 4:30 Tue 11/30


Download
   
Exchange: N/A
Security Type: N/A
Shares Out: 33,980,000
Market Cap: N/A
Last Volume: 0 Avg Vol: 0
52 Week Range: $ - $
Level I Sector: N/A
Level II Sector: N/A
Level III Sector: N/A

Member Indexes:
   

Rankings:
     
Insider 3 Months    :   -
Insider 6 Months    :   -
Insider 3/6 Months :   -
Guru Rank Number :  -
Guru Rank Value     :  -
Guru Occurances    :  -

 

                 
 
Company Profile   Keros Therapeutics is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of treatments for patients suffering from hematological and musculoskeletal disorders. Co.'s primary protein therapeutic product candidate, KER-050, is being developed for the treatment of low blood cell counts, including anemia and thrombocytopenia, in patients with myelodysplastic syndromes, and in patients with myelofibrosis. Co.'s primary small molecule product candidate, KER-047, is being developed for the treatment of anemia resulting from iron imbalance. Co.'s product candidate, KER-012, is being developed for the treatment of pulmonary arterial hypertension.

 
 
Summary  (Direct Transactions Only) 3 Months 6 Months 12 Months 24 Months
Total Shares Bought 0 0 0 0
Total Buy Value $0 $0 $0 $0
Total People Bought 0 0 0 0
Total Buy Transactions 0 0 0 0
Total Shares Sold 0 40,000 80,000 133,250
Total Sell Value $0 $1,811,600 $3,675,839 $5,336,389
Total People Sold 0 1 1 2
Total Sell Transactions 0 1 3 6
End Date 2024-02-01 2023-10-31 2023-05-02 2022-05-02

   
Records found: 130
  Page 1 of 6  
Filer's Name Relation Title Off-Dir-10% Tran. Date Form Action Price Mkt Value D/I Shares Holdings
Rank

  
3m +/-  
Form
   Regnante Keith Chief Financial Officer   •       –      –    2023-11-04 4 AS $45.29 $1,811,600 D/D (40,000) 0     -
   Regnante Keith Chief Financial Officer   •       –      –    2023-11-04 4 OE $16.00 $640,000 D/D 40,000 40,000     -
   Regnante Keith Chief Financial Officer   •       –      –    2023-06-09 4 AS $45.03 $908,367 D/D (20,000) 0     -
   Regnante Keith Chief Financial Officer   •       –      –    2023-06-09 4 OE $16.00 $320,000 D/D 20,000 20,000     -
   Regnante Keith Chief Financial Officer   •       –      –    2023-06-08 4 AS $47.66 $955,872 D/D (20,000) 0     -
   Regnante Keith Chief Financial Officer   •       –      –    2023-06-08 4 OE $16.00 $320,000 D/D 20,000 20,000     -
   Seehra Jasbir Chief Executive Officer   •       •      –    2023-04-08 4 OE $0.48 $1,920 D/D 4,000 252,856     -
   Nussbaum Ran Director   –       •       •   2022-11-29 4 OE $0.00 $1 I/I 7,176 1,226,412     -
   Pontifax Late Stage Gp Ltd. 10% Owner   –       –       •   2022-11-29 4 OE $0.00 $1 I/I 7,176 1,226,412     -
   Kariv Tomer Director   –       •       •   2022-11-29 4 OE $0.00 $1 I/I 7,176 1,226,412     -
   Lachey Jennifer Chief Scientific Officer   •       –      –    2022-07-15 4 AS $30.00 $1,381,020 D/D (46,034) 95,100     -
   Lachey Jennifer Chief Scientific Officer   •       –      –    2022-07-15 4 OE $0.30 $13,810 D/D 46,034 141,134     -
   Lachey Jennifer Chief Scientific Officer   •       –      –    2022-07-13 4 AS $30.00 $57,480 D/D (1,916) 95,100     -
   Lachey Jennifer Chief Scientific Officer   •       –      –    2022-07-13 4 OE $0.30 $575 D/D 1,916 93,184     -
   Seehra Jasbir Chief Executive Officer   •       •      –    2022-06-09 4 OE $0.30 $1,500 D/D 5,000 248,856     -
   Lachey Jennifer Chief Scientific Officer   •       –      –    2022-05-11 4 AS $41.26 $222,050 D/D (5,300) 85,700     -
   Lachey Jennifer Chief Scientific Officer   •       –      –    2022-05-11 4 OE $0.30 $1,590 D/D 5,300 91,000     -
   Lachey Jennifer Chief Scientific Officer   •       –      –    2022-04-11 4 AS $61.37 $332,705 D/D (5,300) 85,700     -
   Lachey Jennifer Chief Scientific Officer   •       –      –    2022-04-11 4 OE $0.30 $1,590 D/D 5,300 91,000     -
   Rovaldi Christopher Chief Operating Officer   •       –      –    2022-04-06 4 AS $65.00 $112,320 D/D (1,728) 0     -
   Rovaldi Christopher Chief Operating Officer   •       –      –    2022-04-06 4 OE $16.00 $27,648 D/D 1,728 1,728     -
   Lachey Jennifer Chief Scientific Officer   •       –      –    2022-04-04 4 AS $60.00 $477,000 D/D (7,950) 85,700     -
   Lachey Jennifer Chief Scientific Officer   •       –      –    2022-04-04 4 OE $0.30 $2,385 D/D 7,950 93,650     -
   Rovaldi Christopher Chief Operating Officer   •       –      –    2022-04-01 4 AS $54.34 $49,675 D/D (864) 0     -
   Rovaldi Christopher Chief Operating Officer   •       –      –    2022-04-01 4 OE $16.00 $13,824 D/D 864 864     -
  130 Records found
  1  2  3  4  5  6   
  Page 1 of 6
  Transaction Code Key: Ownership Code Key
  B - Buy AB - Automatic Buy D - Direct Ownership
  S - Sell AS - Automatic Sell I - Indirect Ownership
  OE - Options Exercised A - Acquired
  IO - Initital Ownership D - Disposed
 
 
    Copyright © 2024 j3sg.com | Disclaimer & Terms of use          Products & Service  About Us  Contact Us